PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Present at Jefferies 2019 Healthcare Conference in London
LYON, France and Cambridge, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen , Chief
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committee opened for patient enrollment in the United States first U.S.
View HTML
Toggle Summary ERYTECH to Host Third Quarter 2019 Conference Call and Business Update on November 8, 2019
LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a Third Quarter
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France LYON, France , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Achieves Milestones in TRYbeCA1 Phase 3 Trial of Eryaspase in Second-line Pancreatic Cancer
Trial opened for patient enrollment in the United States Independent Data Monitoring Committee recommends continuation of the trial as planned LYON, France and CAMBRIDGE, Mass. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers   LYON, France , Oct. 04, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019
Conference call and webcast on Wednesday, September 18 at 2:30 pm CET / 8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on plan Immune modulation collaboration entered into with SQZ Biotechnologies Board strengthened with appointment of Dr.
View HTML
Toggle Summary ERYTECH to Host Second Quarter 2019 Conference Call and Business Update
LYON, France , Sept. 11, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France LYON, France , Aug. 02, 2019 (GLOBE NEWSWIRE) --   Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the
View HTML
Top